No Data
No Data
Stifel Maintains Verve Therapeutics(VERV.US) With Buy Rating
Stifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)
Verve Therapeutics Has Positive Read From NewAmsterdam Data, Says Stifel
One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
Express News | Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)